Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen
Studies Meet Primary Endpoints with 36 and 37 Percent LDL-C Reductions in Severe Hypercholesterolemia and High-Risk Patients
09-Aug-2010 -
Genzyme Corp. and Isis Pharmaceuticals Inc. announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary ...
cholesterol
Genzyme
homozygous familial hypercholesterolemia
+3